Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$14.70
+0.1%
$14.64
$6.41
$14.77
$940.21M0.84757,360 shs2.39 million shs
Geron Co. stock logo
GERN
Geron
$3.79
+6.5%
$2.86
$1.64
$4.05
$2.07B0.6211.07 million shs7.87 million shs
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
$0.89
+11.2%
$0.75
$0.41
$2.05
$88.39M1.02740,199 shs2.89 million shs
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
$3.31
$1.31
$20.89
$2.91M0.76261,432 shs245,100 shs
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$19.50
+0.4%
$19.00
$10.06
$21.72
$366.99M0.8250,264 shs24,217 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.00%0.00%0.00%0.00%0.00%
Geron Co. stock logo
GERN
Geron
-0.56%-4.56%+7.88%+64.81%+46.50%
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
-5.16%+5.39%+12.11%+15.03%-20.19%
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
0.00%0.00%0.00%-40.61%+739.94%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
-0.51%+3.85%-3.33%+6.41%+84.43%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Geron Co. stock logo
GERN
Geron
2.9297 of 5 stars
3.51.00.01.31.81.70.6
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
2.9715 of 5 stars
3.53.00.00.02.91.71.3
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/AN/AN/AN/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
1.8088 of 5 stars
2.53.00.00.02.51.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/A
Geron Co. stock logo
GERN
Geron
3.00
Buy$5.3340.72% Upside
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
3.00
Buy$4.67422.41% Upside
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$24.0023.08% Upside

Current Analyst Ratings

Latest GERN, MDVL, HOOK, AMYT, and NATR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.50 ➝ $5.00
4/11/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
4/10/2024
Geron Co. stock logo
GERN
Geron
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$6.00
3/25/2024
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$5.00
3/25/2024
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.50
3/15/2024
Geron Co. stock logo
GERN
Geron
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$6.00
3/15/2024
Geron Co. stock logo
GERN
Geron
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
3/15/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
3/13/2024
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.50 ➝ $24.00
2/28/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
1/30/2024
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$6.00 ➝ $5.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$222.54M4.22$0.98 per share14.98$5.58 per share2.63
Geron Co. stock logo
GERN
Geron
$240K8,635.99N/AN/A$0.46 per share8.24
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
$20.13M4.39N/AN/A$0.91 per share0.98
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
$43.33M0.00N/AN/A$13.01 per share0.00
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$445.32M0.82$1.59 per share12.24$8.36 per share2.33

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/A
Geron Co. stock logo
GERN
Geron
-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/2/2024 (Confirmed)
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
-$81.58M-$0.88N/AN/AN/A-405.28%-72.30%-40.51%5/9/2024 (Estimated)
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
-$47.62M-$28.72N/AN/AN/A-192.97%-218.10%-103.45%N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.08M$0.7725.32N/A3.39%12.25%7.75%5/7/2024 (Confirmed)

Latest GERN, MDVL, HOOK, AMYT, and NATR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/AN/A  
5/2/2024N/A
Geron Co. stock logo
GERN
Geron
-$0.10N/A+$0.10N/AN/AN/A  
3/22/2024Q4 2023
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
-$0.20-$0.11+$0.09N/A$3.60 million$7.41 million
3/12/2024Q4 2023
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A$0.45+$0.45$0.44N/A$108.94 million
2/28/2024Q4 23
Geron Co. stock logo
GERN
Geron
-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/A
Geron Co. stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
N/AN/AN/AN/AN/A
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.64
1.57
0.94
Geron Co. stock logo
GERN
Geron
0.14
3.16
3.16
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
N/A
3.50
3.50
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.16
1.29

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
71.31%
Geron Co. stock logo
GERN
Geron
73.71%
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
63.88%
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
79.40%

Insider Ownership

CompanyInsider Ownership
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
5.66%
Geron Co. stock logo
GERN
Geron
3.10%
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
5.82%
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
1.50%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
4.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
2,02063.96 million60.34 millionNot Optionable
Geron Co. stock logo
GERN
Geron
141546.87 million529.92 millionOptionable
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
5698.95 million93.19 millionOptionable
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
2791.61 million1.59 millionNo Data
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
81418.82 million17.94 millionOptionable

GERN, MDVL, HOOK, AMYT, and NATR Headlines

SourceHeadline
Some Shareholders May Object To A Pay Rise For Natures Sunshine Products, Inc.s (NASDAQ:NATR) CEO This YearSome Shareholders May Object To A Pay Rise For Nature's Sunshine Products, Inc.'s (NASDAQ:NATR) CEO This Year
finance.yahoo.com - April 26 at 9:49 AM
What Is the Best $20 Stock to Buy in April? 3 Top Picks.What Is the Best $20 Stock to Buy in April? 3 Top Picks.
investorplace.com - April 26 at 6:39 AM
Natures Sunshine Products (NASDAQ:NATR) Shares Pass Above Two Hundred Day Moving Average of $17.98Nature's Sunshine Products (NASDAQ:NATR) Shares Pass Above Two Hundred Day Moving Average of $17.98
americanbankingnews.com - April 26 at 3:44 AM
Natures Sunshines Impact Report Highlights Achievements and Continued Commitment Toward SustainabilityNature's Sunshine's Impact Report Highlights Achievements and Continued Commitment Toward Sustainability
prnewswire.com - April 24 at 10:15 AM
Nature’s Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ETNature’s Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ET
finance.yahoo.com - April 23 at 7:40 PM
Natures Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ETNature's Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ET
globenewswire.com - April 23 at 4:05 PM
Those who invested in Natures Sunshine Products (NASDAQ:NATR) five years ago are up 126%Those who invested in Nature's Sunshine Products (NASDAQ:NATR) five years ago are up 126%
finance.yahoo.com - April 21 at 1:52 PM
Natures Sunshine Products, Inc.s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Nature's Sunshine Products, Inc.'s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
finance.yahoo.com - April 4 at 2:56 PM
Natures Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsNature's Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
finance.yahoo.com - March 15 at 7:55 AM
Natures Sunshine Shares Touch 52-Week High After 4Q UpdateNature's Sunshine Shares Touch 52-Week High After 4Q Update
marketwatch.com - March 14 at 8:49 AM
Why Natures Sunshine (NATR) Stock Is Up TodayWhy Nature's Sunshine (NATR) Stock Is Up Today
finance.yahoo.com - March 13 at 1:46 PM
Natures Sunshine Products, Inc.: Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Products, Inc.: Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - March 13 at 7:45 AM
Natures Sunshine: Q4 Earnings SnapshotNature's Sunshine: Q4 Earnings Snapshot
timesunion.com - March 12 at 8:59 PM
Natures Sunshine (NASDAQ:NATR) Misses Q4 Sales TargetsNature's Sunshine (NASDAQ:NATR) Misses Q4 Sales Targets
finance.yahoo.com - March 12 at 8:59 PM
Natures Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 EarningsNature's Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 Earnings
gurufocus.com - March 12 at 6:04 PM
Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
globenewswire.com - March 12 at 4:05 PM
Preview: Natures Sunshine Productss EarningsPreview: Natures Sunshine Products's Earnings
benzinga.com - March 11 at 3:30 PM
Natures Sunshine (NATR) Q4 Earnings: What To ExpectNature's Sunshine (NATR) Q4 Earnings: What To Expect
finance.yahoo.com - March 11 at 10:30 AM
Nature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
finance.yahoo.com - February 20 at 7:35 PM
Natures Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature's Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
globenewswire.com - February 20 at 4:05 PM
Is There Now An Opportunity In Natures Sunshine Products, Inc. (NASDAQ:NATR)?Is There Now An Opportunity In Nature's Sunshine Products, Inc. (NASDAQ:NATR)?
finance.yahoo.com - February 6 at 10:21 AM
Natures Sunshine Products: Unconvincing Trajectory Despite ImprovementsNature's Sunshine Products: Unconvincing Trajectory Despite Improvements
seekingalpha.com - January 31 at 4:43 AM
Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024
finance.yahoo.com - January 2 at 8:03 PM
Natures Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the companyNature's Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the company
finance.yahoo.com - December 21 at 3:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Amryt Pharma logo

Amryt Pharma

NASDAQ:AMYT
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
Geron logo

Geron

NASDAQ:GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Hookipa Pharma logo

Hookipa Pharma

NASDAQ:HOOK
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
MedAvail logo

MedAvail

NASDAQ:MDVL
MedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. It offers a pharmacy technology solution, including the MedAvail MedCenter, which enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. The company is headquartered in Phoenix, Arizona. On February 2, 2024, MedAvail Holdings, Inc along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Nature

Nature's Sunshine Products

NASDAQ:NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.